



# Nadeem Aslam MBBS, FACE, FACP

\* Nadeem Aslam provides medical services through Dr. Nadeem Aslam Medicine Professional Corporation

Brampton 2979 Bovaird Drive East, Brampton, Ontario, L6S 0C6, Canada

Tel (905) 595-0560

Etobicoke 1723 Kipling Avenue, Suite 2B, Etobicoke, Ontario, M9R 4E1, Canada

Tel (416) 645-1035

## CURRICULUM VITAE

### Education, Certification & Licenses

2020-2022	ICH-GCP Training	TransCelerate
2011	US Board Certified	American Board of Endocrinology
2010	US Board Certified	American Board of Internal Medicine
2001	US Board Certified	American Board of Endocrinology
2000	US Board Certified	American Board of Internal Medicine
1999-2011	Fellowship in Endocrinology and Metabolism	Veterans Affairs Medical Center, USA
1996-1999	Internship and Residency in Internal Medicine	Muhlenberg Hospital, USA
1985-1991	M.B.B.S	Allama Iqbal Medical School, Pakistan
1982-1984	H.Sc. in Pre-medical Sciences	Pakistan Embassy School, Saudi Arabia

### Professional Activities

2017-Present	Principal investigator	LMC Clinical Research Inc.
2013-Present	Sub-Investigator	LMC Clinical Research Inc.
2013-Present	Associate, Endocrinologist	LMC Clinical Research Inc.
Jun 2012-Feb 2013	Private Practice	Central New York, USA
Feb 2012-May 2012	Locum Tenens- Staff Care	Department of Endocrinology, VA Medical Center, USA
Jul 2010-Jan 2012	Medical Director of Endocrinology	Community Hospital, USA
Apr 2009-Mar 2010	Locum Tenens- Staff Care	Vista Health Endocrinology, USA
Aug 2008-Jan 2009	Private Practice	Phoenix, Arizona, USA
Jul 2002-Jul 2008	Associate Medical Director and Endocrinologist	Community Health Center- Arizona, USA
Jul 1999-Sep 2001	Fellowship in Endocrinology, Diabetes & Metabolism	Veterans Affairs Medical Center, USA
Jul 1996-Jun 1999	Residency in Internal Medicine	Muhlenberg Hospital, USA
Apr 1995-Dec 1995	Observership	The Scarborough Grace Hospital, Toronto ON The Mississauga Hospital, Mississauga ON Veterans Affairs Medical Center, USA
Mar 1993-Sep 1994	Student	Kaplan Institute of Toronto, Toronto ON
Aug 1992-Feb 1993	Externship	Khan Polyclinic, Pakistan
Jan 1992-Mar 1992	Externship	Department of Dermatology at Sir Ganga Ram Hospital, Pakistan

### Achievements, Associations & Specialties

Association	Fellow, American Association of Clinical Endocrinologists (AACE)
	Fellow, American College of Physicians (ACP)
	Member, The Endocrine Society
	Member, American Diabetes Association (ADA)
	Member, Canadian Diabetes Association (CDA)
	Member, European Association for the study of Diabetes (EASD)

### Clinical Trials & Research Activities

2013-2020	H9X-MC-GBDJ (Eli Lilly), R727CL1110 (Regeneron), R727CL1118 (Regeneron), 404173-CS2 (ISIS), EFC12626 (Sanofi-aventis), EFC12347 (Sanofi-aventis), M11-352 (Abbott), MK-3102-026 (Merck), TAK-875_304 (Takeda), TAK-875_306 (Takeda), INNOVATE (LMC), MK8835-002 (Merck), 1218.22 (BI), ISIS404173-CS2 (ISIS), APD356-G000-401 (Eisai), B1481022 (Pfizer), B1481038 (Pfizer), 28431754DNE3001 (Janssen Research), B1481045 (Pfizer), D5881C00004 (AstraZeneca), D1690C00024 (AstraZeneca), MK-0431-845 (Merck), M11-352 (AbbVie), LPS14347 (Sanofi), D169AC00001 (AstraZeneca), NN1250-4252 (Novo Nordisk), NN9535-4269 (Novo Nordisk), K-877-302 (KOWA), EFC14834 (Sanofi), EFC14837 (Sanofi), NN1218-4113 (Novo Nordisk), EFC14868 (Sanofi), EFC15294 (Sanofi), EFC14828 (Sanofi), NN1436-4383 (Novo Nordisk), NN1250-4419 (Novo Nordisk), OBS16040 (Sanofi), LPS15544 (Sanofi), 1245-0137 (BI), TRCA-303 (Tricida), PROJ1601 (Ceapro), 20170625 (Amgen), NN9535-4321 (Novo Nordisk), NN9535-4506 (Novo Nordisk), MGL-3196-11 (Madrigal), EX9924-4473 (Novo Nordisk), GS-US-223-1017 (Gilead), 1404-0002 (BI), EFC14875 (Sanofi), D169AC00001 (AstraZeneca), EFC14828 (Sanofi), I8F-MC-GPGM (Eli Lilly), NN9535-4352 (Novo Nordisk), NN1436-4466 (Novo Nordisk), AT-001-2001 (Applied Therapeutic), I8F-MC-GPGM (Lilly), 20180109 (Amgen), Immeditate (LMC), C4491011 (Pfizer), D5676C00001 (AstraZeneca) etc.
1999-2011	Sub-investigator for The VA Cooperative Trial (a seven year prospective randomized study looking at the macrovascular complications in relation to glycemic control in Type 2 Diabetes) "A case of Gamma Hydroxybutyrate (GHB) induced delirium". Muhlenberg Hospital, 1999 "A Multicenter, Open-Label, Utilization Study of Cardizem* CD for the Treatment of Mild to Moderate Hypertension in current Medical Practice". Scarborough Grace Hospital